LTZ Therapeutics Inc., a biotechnology company specializing in immunotherapy with operations in both the US and China, has reportedly raised more than USD 20 million in a Series A financing round. The funding round was led by Lapam Capital, with participation from GL Ventures as well as existing investors Qiming Venture Partners, Shunwei Capital, and K2 Venture Partners.
The capital raised will be directed towards strengthening the development of the company’s product pipelines. This includes the IND filing and initiation of a Phase I study for the CD79B inhibitor LTZ-301, and IND-enabling activities for LTZ-232, a macrophage stimulant. Additionally, the funds will be used to expand LTZ’s global team, supporting the company’s mission to address unmet clinical needs in cancer and autoimmune diseases.
LTZ Therapeutics, equipped with the Myeloid Engager Platform, is committed to leveraging its innovative technology to develop novel therapies that target myeloid cells, a critical component of the immune system, to treat a range of diseases.- Flcube.com
